{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:11:54Z","timestamp":1785553914347,"version":"3.56.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.thromres.2024.109172","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:03:25Z","timestamp":1727193805000},"page":"109172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery"],"prefix":"10.1016","volume":"243","author":[{"given":"Joseph R.","family":"Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Abdulaziz","family":"Almujalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Siegal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar","family":"Dowlatshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Tokessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Buyukdere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2024.109172_bb0005","article-title":"What we have learned about direct oral anticoagulant reversal","volume":"198-203","author":"Siegal","year":"2019","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.thromres.2024.109172_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","article-title":"Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study","volume":"152","author":"Xu","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.109172_bb0015","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109172_bb0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/13696998.2020.1837502","article-title":"Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants","volume":"23","author":"Fermann","year":"2020","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.thromres.2024.109172_bb0025","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109172_bb0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/17474086.2018.1532287","article-title":"Andexanet alfa for the treatment of hemorrhage","volume":"11","author":"Cervi","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.thromres.2024.109172_bb0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1161\/STROKEAHA.120.031108","article-title":"Economic evaluation of andexanet versus prothrombin complex concentrate for reversal of factor Xa-associated intracranial hemorrhage","volume":"52","author":"Micieli","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2024.109172_bb0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.109172_bb0045","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.109172_bb0050","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: A guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2024.109172_bb0055","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000002910","article-title":"Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors","volume":"131","author":"Grottke","year":"2019","journal-title":"Anesthesiology"},{"issue":"Suppl1","key":"10.1016\/j.thromres.2024.109172_bb0060","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate","volume":"93","author":"Van Ryn","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2024.109172_bb0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109172_bb0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jth.12830","article-title":"Multimodal assessment of non-specific hemostatic agents for apixaban reversal","volume":"13","author":"Martin","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0075","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rth2.12089","article-title":"Pharmacological reversal of the direct oral anticoagulants-a comprehensive review of the literature","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0080","article-title":"DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature","author":"Shaw","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0085","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.109172_bb0090","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0095","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/rth2.12336","article-title":"Emergencies on direct oral anticoagulants: management, outcomes, and laboratory effects of prothrombin complex concentrate","volume":"4","author":"Bavalia","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0100","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2024.109172_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians Clinical Practice Guideline","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2024.109172_bb0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109172_bb0115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Haemostasis SoCoAotSaSCotISoTa. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Haemostasis SoCoAotSaSCotISoTa. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0125","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jth.15222","article-title":"Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Khorsand","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0130","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109172_bb0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1747-4949.2010.00579.x","article-title":"Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage","volume":"6","author":"Kosior","year":"2011","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.thromres.2024.109172_bb0140","first-page":"119","article-title":"Approximate is better than \u2018exact\u2019 for interval estimation of binominal proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"Am. Stat."},{"key":"10.1016\/j.thromres.2024.109172_bb0145","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109172_bb0150","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11239-018-1645-y","article-title":"Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study","volume":"45","author":"Piran","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2024.109172_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.07.002","article-title":"Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors","author":"Schulman","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0160","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1055\/s-0043-1771300","article-title":"Effect of PCC on thrombin generation among patients on factor Xa inhibitors with major bleeding or needing urgent surgery (GAUGE): design and rationale","volume":"7","author":"Shaw","year":"2023","journal-title":"TH Open."},{"key":"10.1016\/j.thromres.2024.109172_bb0165","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2024.109172_bb0170","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109172_bb0175","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109172_bb0180","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMe2403726","article-title":"Reversing oral anticoagulation in intracerebral hemorrhage","volume":"390","author":"Smith","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2024.109172_bb0185","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.bja.2024.02.027","article-title":"Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro","volume":"132","author":"Mishima","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.thromres.2024.109172_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","author":"Levy","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0195","article-title":"Heparin insensitivity and thrombotic risk associated with sequential uses of prothrombin complex concentrate and andexanet alfa for apixaban reversal during acute type A aortic dissection repair: a case report","volume":"16","author":"Brenner","year":"2022","journal-title":"A A Pract."},{"key":"10.1016\/j.thromres.2024.109172_bb0200","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjh.13974","article-title":"Safety of prothrombin complex concentrate in healthy subjects","volume":"176","author":"Barco","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.109172_bb0205","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619863493","article-title":"Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0210","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0215","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/jth.13815","article-title":"Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study","volume":"15","author":"Song","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109172_bb0220","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.thromres.2024.04.005","article-title":"Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?","volume":"237","author":"Gendron","year":"2024","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2024.109172_bb0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:46:47Z","timestamp":1729486007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824003049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":45,"alternative-id":["S0049384824003049"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109172","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109172"}}